Pro PG receives S19A RoActemra tocilizumab 162mg/0.9mL PFS and PENS
Updated: Aug 28
Historical supply notice: This article relates to a previous medicine shortage or regulatory approval. Availability and regulatory status may have changed. Healthcare professionals should contact Pro Pharmaceuticals Group to confirm the current supply position.
For current Australian shortage and supply information, see medicine shortages in Australia.
Pro Pharmaceuticals Group has arranged for the supply of the following overseas registered tocilizumab products on a temporary basis:
RoActemra tocilizumab 162mg/0.9mL solution for injection in pre-filled syringe (Roche Germany)
RoActemra tocilizumab 162mg/0.9mL solution for injection in pre-filled pen (Roche Germany)
These products are NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 28 February 2022
Please contact us for more information
